US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Biolipox – Inflazyme Pharmaceuticals Transaction Completed

Biolipox announced today that Inflazyme Pharmaceuticals Ltd., (TSX:IZP) has completed its previously announced sale of substantially all of its research and development assets to the Swedish biopharmaceutical company Biolipox AB. The transaction was approved at Inflazyme’s AGM and Special Meeting of Shareholders on November 16, 2007. Of the votes cast, 98 per cent were in favor of the transaction.Inflazyme has received $4 million in cash for the sale of the PDE inhibitors, the LSAIDs™ and the Protein Therapeutics technology. In addition, Inflazyme may receive up to $7 million in potential

Orexo to acquire Biolipox

– building a specialty pharma company driven by innovationOrexo AB (OMX Nordic List, Mid Cap: ORX) and the principal owners of Biolipox AB have reached an agreement under which Orexo will acquire Biolipox, an innovative Swedish research-based pharmaceutical company that develops new therapies for inflammatory diseases, including pain management and respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).The acquisition will create an innovative specialty pharma company with a broad product pipeline, global partnerships with major financial potential, and

Biolipox Signs Asset Purchase Agreement with Inflazyme Pharmaceuticals

The Swedish biotech company Biolipox AB and Inflazyme Pharmaceuticals Ltd, a Canadian biopharmaceutical company located in Vancouver and listed on the Toronto Stock Exchange (TSX-IZP), have entered into a definitive asset purchase agreement whereby Biolipox will acquire the majority of Inflazyme’s assets for a total gross proceeds of CAD 11 million, plus a potential royalty payment.The assets include Inflazyme’s research and development programs on the LSAIDs™, the PDE inhibitors and the Protein Therapeutics Technology.Biolipox will pay $4 million immediately upon closing of the

Biolipox Interim Report, January – June 2007

• Revenues for the period amounted to SEK 15.6 million (22.0). For the second quarter revenues amounted to SEK 7.9 million (11.0).• Earnings after tax for the period amounted to SEK -57.0 million (-33.5). For the second quarter earnings after tax amounted to SEK -29.4 million (-16.7).• Earnings per share for the period was SEK -75.31 (-49.69). For the second quarter earnings per share was SEK -38.50 (-24.72).• Cash flow for the period was negative and amounted to SEK -43.8 million (positive: 3.6). For the second quarter cash flow was negative and amounted to SEK -22.3 million (-13.4).

Biolipox Interim Report, January - March 2007

- Revenues for the first quarter amounted to SEK 7.8 million (11.1).- Earnings after tax for the first quarter amounted to SEK -27.6 million (-16.8).- Earnings per share for the first quarter was SEK -36.81 (-24.96).- Cash flow for the first quarter was negative and amounted to SEK -21.5 million(positive:16.9).- Drug development projects advance according to plan.Forthcoming financial information- Interim report, January - June 2007 29 August 2007- Interim report, January - September 2007 18 October 2007Biolipox’s interim report 1 January - 31 March 2007, is presented on

Biolipox Year-End Report 2006

* Revenues for the year amounted to SEK 40.5 million (147.0). For the fourth quarter revenues amounted to SEK 7.8 million (147.0).* Earnings after tax for the year amounted to SEK -70.5 million (34.7). For the fourth quarter earnings after tax amounted to SEK -21.3 million (112.6).* Earnings per share for the year was SEK -98.50 (7.80). For the fourth quarter earnings per share was SEK -28.37 (105.56).* Cash flow for the year was negative and amounted to SEK -32.4 million (156.6). For the fourth quarter cash flow was negative and amounted to SEK -23.6 million (88.1).* Biolipox

Biolipox Interim Report, January - September 2006

* Revenues for the first nine months amounted to SEK 32.6 million (0). For the third quarter revenues amounted to SEK 10.6 million (0).* Earnings after tax for the first nine months amounted to SEK -49.2 million (-77.9). For the third quarter earnings after tax amounted to SEK -15.7 million (-24.6).* Earnings per share for the first nine months was SEK -70.12 (-97.77). For the third quarter earnings per share was SEK -22.77 (-31.44).* Cash flow for the first nine months was negative and amounted to SEK -8.8 million (68.5). For the third quarter cash flow was negative and amounted to

Biolipox Interim Report, January - June 2006

* Revenues for the first six months amounted to SEK 22.0 million (0). For the second quarter revenues amounted to SEK 11.0 million (0).* Earnings after tax for the first six months amounted to SEK -33.5 million (loss: 53.3). For the second quarter earnings after tax amounted to SEK -16.7 million (loss: 28.9).* Earnings per share for the first six months was SEK -47.35 (loss: 66.33). For the second quarter earnings per share was SEK -23.69 (loss: 35.56).* Cash flow for the first six months was positive and amounted to SEK 3.6 million (89.5). For the second quarter cash flow was

Biolipox Interim Report, January - March 2006

• Revenues for the first quarter amounted to SEK 11.1 million (0). • Earnings after tax amounted to SEK -16.8 million (-24.4) for the first quarter. • Earnings per share for the first quarter was SEK -23.66 (-30.77). • Cash-flow for the first quarter was positive and amounted to SEK 16.9 million (113.2). • Drug development projects advance according to plan Forthcoming financial information • Interim report, January – June 2006 29 August 2006 • Interim report, January – September 2006 19 October 2006 Biolipox’s interim report for the first quarter 2006 is presented on the following pages.

Biolipox Year-End Report 2005

• Net sales for the fourth quarter amounted to SEK 147.0 million (0). For the full year net sales amounted to SEK 147.0 million (0). • Net income after tax amounted to SEK 116.1 million (loss:24.7) for the fourth quarter. For the full year net income after tax amounted to SEK 46.5 million (loss: 96.7). • Earnings per share for the fourth quarter was SEK 109.11 (loss: 28.70). For the full year earnings per share was SEK 19.59 (loss: 112.26). • Boehringer Ingelheim and Biolipox sign agreement on a new class of drugs to treat pain and inflammation • Biolipox joins top-ranked EU-project •

Boehringer Ingelheim and Biolipox sign agreement on a new class of drugs to treat pain and inflammation

Ingelheim, Germany and Stockholm, Sweden, 14 November 2005 – Boehringer Ingelheim GmbH and Biolipox announced today that they agreed to a worldwide exclusive research and license collaboration. The aim of the collaboration is to develop a new class of drugs with a novel mechanism of action for the treatment of pain and inflammation. Under the terms of the agreement, Boehringer Ingelheim will make an upfront payment, and thereafter milestone and royalty payments. The agreement also includes project specific research funding to Biolipox for a period of three years. Thereafter, Boehringer

Biolipox reports rapid relief with NLA Nasal Spray in new clinical trial

Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases, announced today that it has successfully completed a new clinical study, evaluating the time-to-onset of effect of its new antihistamine treatment, NLA Nasal Spray. The drug was shown to have an onset of effect within 5-10 minutes after intake. This follows the announcement in June 2004 that NLA Nasal Spray had reached the primary efficacy endpoint of a Phase IIa study in patients suffering from allergic rhinitis. These results strongly support the development of NLA Nasal Spray as on-

Biolipox – Year-end report 2004

Full-year 2004• Biolipox secure additional funding – international venture capital firms invest EUR 30 million • NLA Nasal Spray for the treatment of rhinitis shows good efficacy in phase II study • Progress in projects leads to several patent applications • Early drug development organisation further expanded • Net sales amounted to SEK 0 (0) • Results after tax amounted to a loss of SEK 96.7 million (loss: 63.3) • Earnings per share amounted to a loss of SEK 112.25 (loss: 72.46) For the complete Year-end report 2004, please visit www.biolipox.com/finansiella_rapporter.asp For further

Biolipox joins top-ranked EU-project

Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases, today announces that it has been selected to participate in the newly established European network EICOSANOX. This is a unique, multi-disciplinary consortium of highly qualified scientific groups in the area of life sciences, coordinated by the distinguished Karolinska Institutet in Stockholm, Sweden.The European Commission has decided to support the EICOSANOX-consortium as part of the EU 6th Framework Programme. This consortium brings together 12 research centers and biotech companies,

Biolipox successfully completes $41 million financing round – Scandinavian Life Science Venture new investor

Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases announced today that it has successfully completed a $41 million private placement. The Series C round was led by Scandinavian Life Science Venture (SLSV), and included existing investors HealthCap, Apax Partners, Sofinnova Partners, Auriga Partners and Crédit Lyonnais Private Equity. Rigele Abilock, Senior Partner at SLSV has joined Biolipox’s Board of Directors.“We are delighted to complete this financing with such an outstanding syndicate of investors,” says Torbjörn Bjerke, Biolipox’s

Biolipox announces positive results from clinical Phase II trial in rhinitis

Biolipox announces positive results from clinical Phase II trial in rhinitis Biolipox, a research intensive pharmaceutical company targeting inflammation and respiratory diseases, today announced positive preliminary results from the first Phase II clinical trial with NLA (a Novel anti-allergy drug) in patients suffering from allergic rhinitis. Biolipox intends to start discussions with prospective partners, aiming to enter a collaboration agreement for further development and commercialisation of NLA. The targeted product profile for NLA is a drug with significant and rapid reduction of

Year-end report - 2003

Year-end report - 2003 An important year for Biolipox · International venture-capital companies invest SEK 190 million · Clinical phase I study successfully concluded - phase II study initiated · Strengthened - and expanded - project portfolio · Stronger focus on research operations through establishment of an in-house research unit at the Karolinska Institutet · Large increase in number of chemists - intensified search for drug candidates · Biolipox extend cooperation in drug development · Torbjörn Bjerke assumes position as President & CEO · Håkan Åström elected Chairman of the Board ·

Biolipox continues the clinical development of a new hay fever treatment

Biolipox continues the clinical development of a new hay fever treatment Biolipox, a pharmaceutical research and development company in respiratory and inflammation has decided to continue the clinical development of a nasal spray for the treatment of both allergic and non-allergic rhinitis. The decision was taken following the successful completion of clinical Phase I, showing good tolerability of the drug in healthy volunteers. The results from the ongoing Phase IIa study will be available in mid 2004. The world wide rhinitis market is valued at more than US$ 8 billion. Thirty-six

Year-end report - 2003

Year-end report - 2003 An important year for Biolipox - International venture-capital companies invest SEK 190 million - Clinical phase I study successfully concluded - phase II study initiated - Strengthened - and expanded - project portfolio - Stronger focus on research operations through establishment of an in-house research unit at the Karolinska Institutet - Large increase in number of chemists - intensified search for drug candidates - Biolipox extend cooperation in drug development - Torbjörn Bjerke assumes position as President & CEO - Håkan Åström elected Chairman of the Board -

The pharmaceutical company Biolipox strengthens Board of Directors with experienced industry man

The pharmaceutical company Biolipox strengthens Board of Directors with experienced industry man The Biolipox' Board of Directors has appointed Mr Håkan Åström as new President of the Board. Biolipox is a pharmaceutical R&D company with a world-class research profile within the field of inflammatory disease, particularly asthma and allergy. "The opportunity to get involved in the development of Biolipox is very inspiring. I chose Biolipox because the company is active in a field with extended possibilities", says Håkan Åström. "Biolipox' projects have great commercial potential through the

New CEO appointed at drug development company Biolipox

New CEO appointed at drug development company Biolipox The Biolipox Board of Directors has appointed Torbjörn Bjerke as CEO, who will join the company during the month of December. Biolipox is a pharmaceutical R&D company with a world-class research profile within the field of inflammatory disease, particularly asthma and allergy. Torbjörn Bjerke was previously Executive Vice President R&D at ALK-Abello, a world-leading company within allergy immunotherapy. Former start-up CEO, Carl-Johan Dalsgaard, will resume his position as Venture Partner, HealthCap. "Biolipox has the basis for creating

Biolipox expands collaboration with the Karolinska Institutet

Biolipox expands collaboration with the Karolinska Institutet Biolipox, a pharmaceutical R&D company with a world-class research profile within the field of inflammatory disease, particularly asthma and allergy, strengthens an already well-established network of cutting edge competence at the Karolinska Institutet through the expansion of its operations at KI. The Karolinska Institutet will through this collaboration become a shareholder in Biolipox. At the end of the year 2002, Biolipox received confirmation of its accomplishments by raising E21 million in capital, and the company will now

Axovan AG signs agreement with Biolipox AB to discover anti-inflammatory drugs using its integrated GPCR drug discovery

Axovan AG signs agreement with Biolipox AB to discover anti-inflammatory drugs using its integrated GPCR drug discovery platform Allschwil/Basel, Switzerland -- AXOVAN AG, the Swiss GPCR drug discovery company, announced today the signing of a research collaboration with Biolipox AB, a Swedish pharmaceutical R&D company developing novel anti-inflammatory drugs. Under the terms of the agreement, AXOVAN will first identify a specific receptor and will then screen its proprietary GPCR -biased library for compounds that bind effectively to the receptor. The resulting "hit" compounds will be

There are no items matching the current filter
There are no more items matching the current filter
Back to top